The immune system is an important means to control cancer. It is also the source of hematologic malignancies. The goals of the Immunology/Immunotherapy (IMM) Program are to support basic, translational, and clinical research to improve the immune response to cancer, and to translate understanding of hematopoietic cell development into treatment of hematologic malignancies. These goals are encompassed in 3 Specific Aims: 1. to develop and optimize the efficacy of antigen-specific immunotherapeutics; 2. to understand and modulate T cell function and regulation in the tumor microenvironment; 3. to understand normal pathways of hematopoietic cell development and their dysregulation in human hematologic malignancies.
Each aim i ncludes outstanding basic science investigations, and highly collaborative translational initiatives and clinical trials. The Program co-leaders are internationally recognized for their work in tumor antigen identification, induction of tumor-specific CD8 T cell responses, and cancer immunotherapy clinical trials. The Program consists of 30 members and 7 associate members from 9 departments/divisions in the School of Medicine. Total extramural funding is over $11.17M, including over $4.04M from the NCI and over $4.77M from other NIH institutes. Program members have published 216 papers over the last 5 years, of which 12% were inter-programmatic and 16% were intraprogrammatic. The Program supports research in progress presentations and seminars to engender new directions and collaborations; pilot funding to encourage development of promising collaborations and ideas; and an Immune Monitoring Laboratory to facilitate clinical research. Seventeen clinical trials led by Program members are open to enrollment across 5 cancer histologies (pancreatic cancer, breast cancer, head and neck cancer, prostate cancer, and melanoma). They include 10 investigator-initiated trials, of which three are multicenter. These trials are evaluating cancer vaccines, checkpoint blockade antibodies and combination immunotherapies. These trials test hypotheses arising from laboratory science and also bring tissue to the laboratories to investigate cellular processes and molecular mechanisms to explain the clinical findings. This Program provides a firm foundation for continued advances in understanding of the immune system and utilizing that knowledge to improve immunotherapy and treatment of hematologic malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-30
Application #
10091450
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-09-16
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
30
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Melhuish, Tiffany A; Kowalczyk, Izabela; Manukyan, Arkadi et al. (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861:983-995
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245
Carlton, Anne L; Illendula, Anuradha; Gao, Yan et al. (2018) Small molecule inhibition of the CBF?/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition. Gynecol Oncol 149:350-360
Kulling, Paige M; Olson, Kristine C; Olson, Thomas L et al. (2018) Calcitriol-mediated reduction in IFN-? output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. J Steroid Biochem Mol Biol 177:140-148
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562

Showing the most recent 10 out of 539 publications